Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 1.1% – Here’s Why

Posted by Teresa Graham on Mar 13th, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) traded down 1.1% during trading on Tuesday . The stock traded as low as $12.35 and last traded at $13.32. 357,987 shares changed hands during trading, a decline of 41% from the average session volume of 604,027 shares. The stock had previously closed at $13.47.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating on the stock.

Check Out Our Latest Analysis on TNXP

Tonix Pharmaceuticals Stock Performance

The company has a market cap of $25.49 million, a P/E ratio of 0.00 and a beta of 2.23. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average price of $20.01 and a two-hundred day moving average price of $20.24.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Large investors have recently modified their holdings of the business. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $40,000. Two Sigma Investments LP acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $66,000. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $72,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $162,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $526,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.